Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.

Humayoun NikkhahReza Niazpour MoezMorteza EntezariAlireza RamezaniKiana HassanpourSaeed KarimiMehdi Yaseri

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2021)

Topical ketorolac 0.5% three times a day could enhance and sustain the efficacy of intravitreal bevacizumab in the treatment of DME.

Keyphrases

vascular endothelial growth factor
diabetic retinopathy
placebo controlled
double blind
clinical trial
age related macular degeneration
metastatic colorectal cancer
smoking cessation
optical coherence tomography
phase ii study